Cellvation
Clinical-stage biopharmaceutical company developing cellular therapeutics and supporting technologies to treat severe traumatic brain injury (TBI). Programs include autologous bone marrow-derived cell therapy clinical development and a mechanotransduction-based bioreactor to enhance anti-inflammatory properties of marrow-derived cells. Activities include preclinical in vivo studies, Phase 1/2 clinical trials, regulatory interactions and academic licensing/partnerships.
Industries
Nr. of Employees
small (1-50)
Cellvation
Nyack, New York, United States, North America
Products
Autologous bone marrow-derived mononuclear cell therapy for severe TBI
Clinical-stage autologous bone marrow mononuclear cell product developed for intravenous administration to adults and children with severe traumatic brain injury; advanced through Phase 1 and Phase 2 studies.
Bioreactor for mechanotransductive conditioning of bone marrow-derived cells
Device and process to expose bone marrow-derived adherent cells to controlled shear stress to upregulate anti-inflammatory gene programs and enhance therapeutic potency without genetic modification; prototyped for human-scale dose production.
Autologous bone marrow-derived mononuclear cell therapy for severe TBI
Clinical-stage autologous bone marrow mononuclear cell product developed for intravenous administration to adults and children with severe traumatic brain injury; advanced through Phase 1 and Phase 2 studies.
Bioreactor for mechanotransductive conditioning of bone marrow-derived cells
Device and process to expose bone marrow-derived adherent cells to controlled shear stress to upregulate anti-inflammatory gene programs and enhance therapeutic potency without genetic modification; prototyped for human-scale dose production.
Services
Academic and industry partnership development
Engagement with academic groups and industry partners to license, co-develop or co-fund cellular therapy programs for TBI.
Academic and industry partnership development
Engagement with academic groups and industry partners to license, co-develop or co-fund cellular therapy programs for TBI.
Expertise Areas
- Cell therapy development
- Traumatic brain injury therapeutics
- Clinical trial management for autologous cell therapies
- Mechanotransduction-based cell conditioning
Key Technologies
- Autologous bone marrow-derived cell therapy
- Bioreactor mechanotransduction (wall shear stress) conditioning
- Mesenchymal stromal cell immunomodulation
- IV cell delivery